Phathom Pharmaceuticals

Yahoo Finance • 2 days ago

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

DelveInsight Business Research LLP The eosinophilic esophagitis market is witnessing steady growth, primarily driven by the increasing awareness leading to standardized diagnosis and high relapse rates that continue to fuel ongoing treatm... Full story

Yahoo Finance • 19 days ago

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Quick Read Phathom Pharmaceuticals (PHAT) saw quarterly prescription fills jump from 127,000 in Q1 2025 to 273,000 in Q4 2025, driving Q4 revenue to $57.58M (up 94% year-over-year) with EPS of -$0.08 beating consensus by -$0.34, while Bar... Full story

Yahoo Finance • last month

Noteworthy Thursday Option Activity: INTU, AMPX, PHAT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intuit Inc (Symbol: INTU), where a total of 32,692 contracts have traded so far, representing approximately 3.3 million underlying... Full story

Yahoo Finance • 2 months ago

Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit

Phathom Pharmaceuticals logo Key Points Phathom is building its business around VOQUEZNA (vonoprazan), reporting $55 million in 2024 revenue and an estimated $175 million for 2025, and expects to reach operating profitability in the seco... Full story

Yahoo Finance • 4 months ago

Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks

As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained unpredictable as President Trump contin... Full story

Yahoo Finance • 5 months ago

Surprising Analyst 12-Month Target For ITOT

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heart... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and c... Full story

Yahoo Finance • 8 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include a... Full story

Yahoo Finance • 8 months ago

Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth

Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2025 MANAGEMENT VIEW * Steven L. Basta, CEO, indicated that the quarter marked "a meaningful inflection point for Phathom" as the company builds a growth-oriented and profitable... Full story

Yahoo Finance • 8 months ago

Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket

PHATHOM PHARMACEUTICALS (NASDAQ:PHAT) BEATS Q2 REVENUE AND EPS ESTIMATES, SHARES RISE IN PREMARKET Phathom Pharmaceuticals (NASDAQ:PHAT [https://www.chartmill.com/stock/quote/PHAT]) reported second-quarter 2025 financial results that surp... Full story

Yahoo Finance • 9 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story

Yahoo Finance • 10 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story

Yahoo Finance • 10 months ago

Phathom says FDA confirmed Voqueza exclusivity through May 2032

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images * Phathom Pharmaceuticals (NASDAQ:PHAT [https://seekingalpha.com/symbol/PHAT]) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezn... Full story

Yahoo Finance • 10 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story

Yahoo Finance • 10 months ago

Phathom surges 125% after FDA grants petition on Voquezna exclusivity

[Going Up] Richard Drury Phathom Pharmaceuticals has shot up ~125% in Friday trading after the U.S. FDA granted their Citizen Petition regarding the expiration date of new chemical entity exclusivity for their drug Voquezna (vonoprazan).... Full story

Yahoo Finance • 10 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and co... Full story

Yahoo Finance • 12 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story

Yahoo Finance • 12 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced th... Full story

Yahoo Finance • last year

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced tod... Full story